Cryopyrin-associated periodic syndromes: 2026 so far

Routine-care reports highlighted remission with IL-1 blockade and dose changes.

In the months covered, the most treatment-relevant update came from a real-world cohort of 51 Turkish-origin children. Many in the Turkey cohort were reported to reach remission while receiving IL-1 blocking medicines (drugs that block the inflammatory signal IL-1) such as canakinumab or anakinra. Dose adjustments, including higher-than-standard dosing, were commonly reported in that cohort. In contrast, over half of the Germany cohort were reported to be in remission without ongoing treatment at last follow-up, but the report did not explain why these differences occurred. This supports the idea that remission in routine care was sometimes reported alongside IL-1 blocker dose changes, while some groups with milder variants were reported to do well without ongoing medicine.

Research covered in: April 2026

Reports added broader context and specific cohorts on amyloidosis burden.

Between February and September 2026, several reports added context that AA amyloidosis (a protein build-up that can damage organs) can be a high-impact complication even if it is not frequent. A French referral-center review described AA amyloidosis as uncommon overall across monogenic autoinflammatory diseases, with only a small number of CAPS cases included. It also noted substantial kidney burden in the overall AA group (including kidney transplant during follow-up) and that AA amyloidosis was identified before the autoinflammatory diagnosis in 40% of cases. Separately, a large referral cohort reported AA amyloidosis in 20% of patients diagnosed with late-onset mosaic CAPS. A single-child case report described early AA amyloidosis with kidney function stabilization after anakinra. Together, these reports show AA amyloidosis appearing in both cohort and case-report settings and, when present, being closely tied to serious kidney involvement and sometimes showing up before the underlying diagnosis was recognized.

Research covered in: May 2026, July 2026, September 2026

More evidence emphasized mosaic variants and uncertain variants in diagnosis.

So far in 2026, the available reports reinforced that genetic results in CAPS can include low-level mosaic variants (a change present in only some cells) and variants of uncertain significance (a change with unclear meaning). These findings were presented as important for diagnosis and for understanding expected severity patterns. A large referral cohort found mosaic variants in 83 of 403 people with a systemic autoinflammatory diagnosis, with CAPS accounting for about 24% of mosaic diagnoses, including very low-level variants in blood testing. In a separate real-world pediatric cohort, children with clearly disease-causing NLRP3 mutations tended to have higher disease activity and more severe clinical pictures. Those with variants of uncertain significance (including Q703K) tended to have milder disease and different flare patterns. In practical terms, these reports repeatedly pointed to sensitive sequencing and careful variant interpretation as helpful for explaining atypical or milder/late-onset presentations and for making sense of why disease burden varies.

Research covered in: April 2026, July 2026

Reports highlighted milder-group flare triggers and perioperative temperature monitoring.

In the months covered, one real-world cohort reported that, in a milder-variant group, infection-triggered attacks were noted more often and gastrointestinal symptoms were noted more often. Separately, a single-patient report on Muckle-Wells syndrome (a CAPS subtype) highlighted perioperative considerations (planning around surgery), especially close temperature monitoring during anesthesia (medicine used to keep you asleep for a procedure) for a biopsy. These reports underline that both everyday patterns (like infection-associated flares and digestive symptoms) and less common situations (like surgery) may lead clinicians to plan and monitor in CAPS-specific ways.

Research covered in: April 2026

Multiple lab studies proposed new levers on NLRP3 activation.

From February through September 2026, several lab and animal studies explored ways NLRP3-driven inflammation might be modulated, without testing clinical benefit in people. A CAPS-like mouse model suggested that two NLRP3 inhibitors could look similar for peripheral inflammation, but only a brain-penetrant inhibitor reduced brain inflammation signals and immune cell build-up in brain tissue. Other lab work described cofilin-1 as a natural brake (a built-in slowing mechanism) on NLRP3 that can be weakened by oxidative stress, reported peptides based on the cofilin-1 binding region that suppressed inflammasome activation (turning on of an inflammatory protein complex) in lab/ex vivo settings, and found circadian clock proteins (CRY1/CRY2) influenced NLRP3 activation and MCC950 blocking under time-of-day conditions in cells. Overall, these preclinical results point to possible future treatment ideas (brain access, clock timing, protein-protein brakes, neutrophil trap/PAD4 pathways), but they did not show effects on symptoms or outcomes in people.

Research covered in: February 2026, March 2026, May 2026, July 2026